CN111825679A - Novel spiro-pyrrole [2, 1-b ] quinazolinone derivative and preparation method and application thereof - Google Patents
Novel spiro-pyrrole [2, 1-b ] quinazolinone derivative and preparation method and application thereof Download PDFInfo
- Publication number
- CN111825679A CN111825679A CN202010640945.5A CN202010640945A CN111825679A CN 111825679 A CN111825679 A CN 111825679A CN 202010640945 A CN202010640945 A CN 202010640945A CN 111825679 A CN111825679 A CN 111825679A
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- added
- solvent
- yield
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title claims abstract description 21
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims abstract description 32
- 125000003003 spiro group Chemical group 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims description 266
- 239000002904 solvent Substances 0.000 claims description 115
- 150000001875 compounds Chemical class 0.000 claims description 110
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 100
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 93
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 70
- 238000003756 stirring Methods 0.000 claims description 66
- 239000000243 solution Substances 0.000 claims description 59
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 56
- 229960001701 chloroform Drugs 0.000 claims description 52
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 51
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 50
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 50
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 42
- 239000005457 ice water Substances 0.000 claims description 41
- 238000001035 drying Methods 0.000 claims description 37
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 27
- 238000000967 suction filtration Methods 0.000 claims description 27
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 25
- 229940126214 compound 3 Drugs 0.000 claims description 16
- 229940125898 compound 5 Drugs 0.000 claims description 16
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims description 14
- 229940125782 compound 2 Drugs 0.000 claims description 14
- 229940125904 compound 1 Drugs 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 229910015900 BF3 Inorganic materials 0.000 claims description 7
- -1 spiro pyrrolo [2, 1-b ] quinazolinone derivative Chemical class 0.000 claims description 7
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- JWIPGAFCGUDKEY-UHFFFAOYSA-L O[Cr](Cl)(=O)=O.C1=CC=NC=C1 Chemical compound O[Cr](Cl)(=O)=O.C1=CC=NC=C1 JWIPGAFCGUDKEY-UHFFFAOYSA-L 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 137
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 96
- 239000012043 crude product Substances 0.000 description 72
- 239000003480 eluent Substances 0.000 description 71
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- 238000003760 magnetic stirring Methods 0.000 description 56
- 238000004440 column chromatography Methods 0.000 description 47
- 239000012074 organic phase Substances 0.000 description 47
- 238000000605 extraction Methods 0.000 description 46
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 31
- 238000003786 synthesis reaction Methods 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 25
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- 238000010791 quenching Methods 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 23
- 229910002027 silica gel Inorganic materials 0.000 description 23
- 238000010898 silica gel chromatography Methods 0.000 description 23
- LJRWLSKYGWLYIM-UHFFFAOYSA-N 3-trimethylsilylprop-2-ynal Chemical compound C[Si](C)(C)C#CC=O LJRWLSKYGWLYIM-UHFFFAOYSA-N 0.000 description 18
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 18
- 239000003208 petroleum Substances 0.000 description 18
- 238000001816 cooling Methods 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 238000009210 therapy by ultrasound Methods 0.000 description 9
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KYPJODYLZIOMTO-UHFFFAOYSA-N 3-trimethylsilylprop-2-enal Chemical compound C[Si](C)(C)C=CC=O KYPJODYLZIOMTO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- ASQOQJYHIYYTEJ-GBESFXJTSA-N (1r,7s,9as)-7-decyl-2,3,4,6,7,8,9,9a-octahydro-1h-quinolizin-1-ol Chemical compound O[C@@H]1CCCN2C[C@@H](CCCCCCCCCC)CC[C@H]21 ASQOQJYHIYYTEJ-GBESFXJTSA-N 0.000 description 2
- ZXCUOCHXNYWBBG-ZQWQDMLBSA-N (1s,2s,3s,4s)-3,4-bis[2-methylpropyl-[(4-phenoxyphenyl)methyl]carbamoyl]cyclobutane-1,2-dicarboxylic acid Chemical compound O=C([C@H]1[C@@H]([C@@H]([C@H]1C(O)=O)C(O)=O)C(=O)N(CC(C)C)CC=1C=CC(OC=2C=CC=CC=2)=CC=1)N(CC(C)C)CC(C=C1)=CC=C1OC1=CC=CC=C1 ZXCUOCHXNYWBBG-ZQWQDMLBSA-N 0.000 description 2
- GNPHAOQLHRZODS-ZQWQDMLBSA-N (1s,2s,3s,4s)-3,4-bis[butyl-[(4-phenoxyphenyl)methyl]carbamoyl]cyclobutane-1,2-dicarboxylic acid Chemical compound O=C([C@H]1[C@@H]([C@@H]([C@H]1C(O)=O)C(O)=O)C(=O)N(CCCC)CC=1C=CC(OC=2C=CC=CC=2)=CC=1)N(CCCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 GNPHAOQLHRZODS-ZQWQDMLBSA-N 0.000 description 2
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 2
- KRIWIRSMQRQYJG-DLBZAZTESA-N (2s,3s)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol Chemical compound C=1C(N[C@@H](CO)[C@H](O)CO)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1 KRIWIRSMQRQYJG-DLBZAZTESA-N 0.000 description 2
- LPNRUMVKXCLEBE-JXVRESAISA-L (3r)-4-[[(e)-2-[5-ethyl-4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethenyl]-oxidophosphoryl]-3-hydroxybutanoate Chemical compound CCC1=C(C=2C=CC=CC=2)N=C(C(C)C)C(\C=C\P([O-])(=O)C[C@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 LPNRUMVKXCLEBE-JXVRESAISA-L 0.000 description 2
- MZCZXPHMOGJQBJ-OAQYLSRUSA-L (3r)-4-[[4-(4-fluorophenyl)-2-propan-2-yl-6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-c]pyridin-3-yl]methoxy-oxidophosphoryl]-3-hydroxybutanoate Chemical compound [O-]C(=O)C[C@@H](O)CP([O-])(=O)OCC=1C(C(C)C)=NC(C2=CC=CC=C2CCC2)=C2C=1C1=CC=C(F)C=C1 MZCZXPHMOGJQBJ-OAQYLSRUSA-L 0.000 description 2
- COXVPYKZDDKVRF-ULQDDVLXSA-N (4,4-difluorocyclohexyl)methyl N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C=O)NC(=O)OCC2CCC(CC2)(F)F COXVPYKZDDKVRF-ULQDDVLXSA-N 0.000 description 2
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 2
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 2
- QVBVQHTXLPNXEY-ZMFCMNQTSA-N (4r)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 QVBVQHTXLPNXEY-ZMFCMNQTSA-N 0.000 description 2
- QBTROWHSMGZXCV-RQURQNPSSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecoxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QBTROWHSMGZXCV-RQURQNPSSA-N 0.000 description 2
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 2
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 2
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- AHZCYZMNFBGXAC-UHFFFAOYSA-N 1-[[5-chloro-2-(trifluoromethyl)phenyl]methyl]-7-(2-piperazin-1-ylpyridin-4-yl)-3,4-dihydro-2h-pyrido[2,3-b]pyrazine Chemical compound FC(F)(F)C1=CC=C(Cl)C=C1CN1C2=CC(C=3C=C(N=CC=3)N3CCNCC3)=CN=C2NCC1 AHZCYZMNFBGXAC-UHFFFAOYSA-N 0.000 description 2
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 2
- ORQHHLPTMSGMQT-UHFFFAOYSA-N 2-[4-(5-fluoropyridin-2-yl)piperazin-1-yl]-n-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide Chemical compound N1=CC(F)=CC=C1N1CCN(CC(=O)NC=2SC=3CCCCC=3N=2)CC1 ORQHHLPTMSGMQT-UHFFFAOYSA-N 0.000 description 2
- YLLRPQWLASQXSI-UHFFFAOYSA-N 3-(4b,8a,9,9a-tetrahydro-4aH-pyrido[2,3-b]indol-4-ylamino)phenol Chemical compound Oc1cccc(NC2=CC=NC3NC4C=CC=CC4C23)c1 YLLRPQWLASQXSI-UHFFFAOYSA-N 0.000 description 2
- XDCOYBQVEVSNNB-UHFFFAOYSA-N 4-[(7-naphthalen-2-yl-1-benzothiophen-2-yl)methylamino]butanoic acid Chemical compound OC(=O)CCCNCc1cc2cccc(-c3ccc4ccccc4c3)c2s1 XDCOYBQVEVSNNB-UHFFFAOYSA-N 0.000 description 2
- LIDUGWDLSDKCLM-CSKARUKUSA-N 4-[[3-[[[(e)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenoxy]methyl-dimethylsilyl]benzonitrile Chemical compound CC(C)(C)C#C/C=C/CN(CC)CC1=CC=CC(OC[Si](C)(C)C=2C=CC(=CC=2)C#N)=C1 LIDUGWDLSDKCLM-CSKARUKUSA-N 0.000 description 2
- OJKONCJPCULNOW-DYVFJYSZSA-N 5-chloro-2-fluoro-4-[(1s,2r)-2-(2-methylpyrazol-3-yl)cyclohexyl]oxy-n-pyrimidin-4-ylbenzenesulfonamide Chemical compound CN1N=CC=C1[C@@H]1[C@@H](OC=2C(=CC(=C(F)C=2)S(=O)(=O)NC=2N=CN=CC=2)Cl)CCCC1 OJKONCJPCULNOW-DYVFJYSZSA-N 0.000 description 2
- UFMQJYHLIUACCG-UHFFFAOYSA-N 8-nitroindolo[2,1-b]quinazoline-6,12-dione Chemical compound C1=CC=C2C(=O)N3C4=CC=C([N+](=O)[O-])C=C4C(=O)C3=NC2=C1 UFMQJYHLIUACCG-UHFFFAOYSA-N 0.000 description 2
- 229940126559 Compound 4e Drugs 0.000 description 2
- 229940125761 Compound 6g Drugs 0.000 description 2
- HSWVJQBEXRKOBZ-QGZVFWFLSA-N FC1=C(OC2CCN(CC2)C=2N=C3C(=NC=2N[C@H]2COCC2)CN(CC3)C(C)=O)C=CC(=C1)F Chemical compound FC1=C(OC2CCN(CC2)C=2N=C3C(=NC=2N[C@H]2COCC2)CN(CC3)C(C)=O)C=CC(=C1)F HSWVJQBEXRKOBZ-QGZVFWFLSA-N 0.000 description 2
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 2
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 2
- 229940125907 SJ995973 Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940125872 compound 4d Drugs 0.000 description 2
- 229940126115 compound 4f Drugs 0.000 description 2
- 229940125880 compound 4j Drugs 0.000 description 2
- 229940126136 compound 5i Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- JBLLRCOZJMVOAE-HSQYWUDLSA-N n-[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methoxy-1h-indole-2-carboxamide Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)C=1NC=2C=CC=C(C=2C=1)OC)C(=O)C=1SC2=CC=CC=C2N=1)[C@@H]1CCNC1=O JBLLRCOZJMVOAE-HSQYWUDLSA-N 0.000 description 2
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- BHLXTPHDSZUFHR-UHFFFAOYSA-N varespladib Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=CC=C2N1CC1=CC=CC=C1 BHLXTPHDSZUFHR-UHFFFAOYSA-N 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- QMGHHBHPDDAGGO-IIWOMYBWSA-N (2S,4R)-1-[(2S)-2-[[2-[3-[4-[3-[4-[[5-bromo-4-[3-[cyclobutanecarbonyl(methyl)amino]propylamino]pyrimidin-2-yl]amino]phenoxy]propoxy]butoxy]propoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound CN(CCCNC1=NC(NC2=CC=C(OCCCOCCCCOCCCOCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C=C3)C3=C(C)N=CS3)C(C)(C)C)C=C2)=NC=C1Br)C(=O)C1CCC1 QMGHHBHPDDAGGO-IIWOMYBWSA-N 0.000 description 1
- IZGDXVLRMHXOJV-SFHVURJKSA-N (3s)-4-[2-[2-(4-fluoro-3-methylphenyl)-4-methyl-6-propan-2-ylphenyl]ethyl-hydroxyphosphoryl]-3-hydroxybutanoic acid Chemical compound CC(C)C1=CC(C)=CC(C=2C=C(C)C(F)=CC=2)=C1CCP(O)(=O)C[C@@H](O)CC(O)=O IZGDXVLRMHXOJV-SFHVURJKSA-N 0.000 description 1
- RTTUBUXMNUJHRR-DXRVJIQQSA-N (3s)-4-[[(e)-2-[1-(4-fluorophenyl)-3-propan-2-ylindol-2-yl]ethenyl]-hydroxyphosphoryl]-3-hydroxybutanoic acid Chemical compound C12=CC=CC=C2C(C(C)C)=C(\C=C\P(O)(=O)C[C@@H](O)CC(O)=O)N1C1=CC=C(F)C=C1 RTTUBUXMNUJHRR-DXRVJIQQSA-N 0.000 description 1
- AOSODOHQJJPEAM-VUVZNRFTSA-N (3s)-4-[[(e)-2-[3'-(4-fluorophenyl)spiro[cyclopentane-1,1'-indene]-2'-yl]ethenyl]-hydroxyphosphoryl]-3-hydroxybutanoic acid Chemical compound OC(=O)C[C@H](O)CP(O)(=O)\C=C\C1=C(C=2C=CC(F)=CC=2)C2=CC=CC=C2C11CCCC1 AOSODOHQJJPEAM-VUVZNRFTSA-N 0.000 description 1
- WHQUHTXULUACFD-KRWDZBQOSA-N (3s)-4-[[2-(4-fluoro-3-methylphenyl)-4-methyl-6-propan-2-ylphenyl]methoxy-hydroxyphosphoryl]-3-hydroxybutanoic acid Chemical compound CC(C)C1=CC(C)=CC(C=2C=C(C)C(F)=CC=2)=C1COP(O)(=O)C[C@@H](O)CC(O)=O WHQUHTXULUACFD-KRWDZBQOSA-N 0.000 description 1
- MNIPVWXWSPXERA-IDNZQHFXSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecanoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)CCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 MNIPVWXWSPXERA-IDNZQHFXSA-N 0.000 description 1
- BOOYHBPHFVNWNH-OAHLLOKOSA-N 1-tert-butyl-6-[[(1R)-1-(4-chlorophenyl)ethyl]amino]-5-[(4-fluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C[C@H](C1=CC=C(C=C1)Cl)NC2=NC3=C(C=NN3C(C)(C)C)C(=O)N2CC4=CC=C(C=C4)F BOOYHBPHFVNWNH-OAHLLOKOSA-N 0.000 description 1
- TXJUTRJFNRYTHH-UHFFFAOYSA-N 1h-3,1-benzoxazine-2,4-dione Chemical compound C1=CC=C2C(=O)OC(=O)NC2=C1 TXJUTRJFNRYTHH-UHFFFAOYSA-N 0.000 description 1
- GEQNZVKIDIPGCO-UHFFFAOYSA-N 2,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C(OC)=C1 GEQNZVKIDIPGCO-UHFFFAOYSA-N 0.000 description 1
- PSWDQTMAUUQILQ-UHFFFAOYSA-N 2-[(6-methoxy-4-methylquinazolin-2-yl)amino]-5,6-dimethyl-1h-pyrimidin-4-one Chemical compound N1=C(C)C2=CC(OC)=CC=C2N=C1NC1=NC(=O)C(C)=C(C)N1 PSWDQTMAUUQILQ-UHFFFAOYSA-N 0.000 description 1
- JWHYSEDOYMYMNM-QGZVFWFLSA-N 2-[4-[(2r)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C([C@@H](OCC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(C(F)(F)F)C=C1 JWHYSEDOYMYMNM-QGZVFWFLSA-N 0.000 description 1
- YBAGMTVKDRIMTB-UHFFFAOYSA-N 2-bromo-4-methoxyaniline Chemical compound COC1=CC=C(N)C(Br)=C1 YBAGMTVKDRIMTB-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- LJWAPDSCYTZUJU-UHFFFAOYSA-N 3-fluoro-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1F LJWAPDSCYTZUJU-UHFFFAOYSA-N 0.000 description 1
- NFWPZNNZUCPLAX-UHFFFAOYSA-N 4-methoxy-3-methylaniline Chemical compound COC1=CC=C(N)C=C1C NFWPZNNZUCPLAX-UHFFFAOYSA-N 0.000 description 1
- 229940126650 Compound 3f Drugs 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AKQOBHZKBDHWQI-BZEFIUHZSA-N O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O Chemical compound O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O AKQOBHZKBDHWQI-BZEFIUHZSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HFIVLLBFACNAFN-UHFFFAOYSA-N [1-amino-2-[2-(4-methoxyphenyl)ethylamino]ethyl]phosphonic acid Chemical compound COc1ccc(CCNCC(N)P(O)(O)=O)cc1 HFIVLLBFACNAFN-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- CDVMXMZPDJHSCC-UHFFFAOYSA-N chembl1684662 Chemical compound C=1C=C2C=C(C=3C4=NC=CC=C4NN=3)NC2=CC=1CC(=O)C1=CC=CC=C1 CDVMXMZPDJHSCC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229940125796 compound 3d Drugs 0.000 description 1
- 229940127108 compound 5g Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- CDGNLUSBENXDGG-UHFFFAOYSA-N meta-Cresidine Chemical compound COC1=CC=C(N)C(C)=C1 CDGNLUSBENXDGG-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a new spiro pyrrole [2, 1-b ] quinazolinone derivative, a preparation method and application thereof, wherein the new spiro pyrrole [2, 1-b ] quinazolinone derivative is synthesized by a simple method, the yield is high, the production cost is low, the obtained new spiro pyrrole [2, 1-b ] quinazolinone derivative has good anticancer effect on different tumor cells, can be prepared into anticancer drugs of various dosage forms, and has high medical value and wide market prospect.
Description
Technical Field
The invention relates to the field of medicinal chemistry, in particular to a novel spiro pyrrole [2, 1-b ] quinazolinone derivative, a preparation method and application thereof.
Background
The tumor is a common disease and frequently encountered disease, wherein malignant tumor has become a main disease threatening human health, and the morbidity and mortality of the malignant tumor are the first of all diseases. In 2 months of 2017, the national cancer center issues the latest Chinese cancer data, and the data shows that about 1 million people in China can diagnose cancer every day, namely about 7 people per minute. Quinazolinone is an important nitrogen-containing heterocyclic compound, is one of the most important structural units in medicinal chemistry, and has wide pharmacological activities such as anti-inflammation, anti-tumor, anti-convulsion, sedation, anti-hypertension, vasodilation, antimicrobial and antibacterial. And thus has been a focus of research by organic synthesis and pharmaceutical chemists. The quinazolone pentacyclic skeleton is one of the more concerned pentacyclic skeletons in the quinazolone compound, and attracts a plurality of synthetic and pharmaceutical chemists to synthesize, modify and study the skeletons and pharmacological activity in recent years.
The novel spiro pyrrole [2, 1-b ] quinazolinone derivatives have various biological activities, have wide application, are easy to cause side reactions in the synthesis process, have low yield and have very limited synthesis method.
Disclosure of Invention
The invention aims to: aiming at the problems, the invention provides a novel spiro pyrrole [2, 1-b ] quinazolinone derivative with high yield and good anti-tumor effect, and a preparation method and application thereof.
The invention is realized by the following technical scheme:
the present invention provides: a new spiro pyrrole [2, 1-b ] quinazolinone derivative has a structural formula shown in formula I,
wherein R is1Is H, F, Cl, Br, OMe, Me, NO2Or CF3;R2H, F, Br, OMe or Me; r3Is H or Me.
Further, the structural formula of the novel spiro pyrrole [2, 1-b ] quinazolinone derivative is shown as follows:
the invention also provides a preparation method of the novel spiro pyrrole [2, 1-b ] quinazolinone derivative, which comprises the following steps:
(1) preparation of compound 3: adding the compound 1, the compound 2 and water into a reaction container in sequence, heating, stirring for reaction, after the reaction is finished, performing suction filtration, taking filter residues, washing and drying to obtain a compound 3;
(2) preparation of compound 4: adding the compound 3, p-toluenesulfonic acid, tetrahydrofuran, anhydrous magnesium sulfate and 3-trimethylsilyl propiolic aldehyde into a reaction vessel in sequence, and reacting at room temperature; adding DDQ in an ice water bath for reaction, removing the solvent after the reaction is finished, and purifying to obtain a compound 4;
(3) preparation of compound 5: adding the compound 4, acetone and silver nitrate aqueous solution into a reaction vessel in sequence, stirring and reacting under the condition of keeping out of the sun, removing the solvent after the reaction is finished, and purifying to obtain a compound 5;
(4) preparing a target product 6: adding the compound 5, palladium acetate, boron trifluoride diethyl etherate solution and trichloromethane into a reaction vessel in sequence, heating, reacting, removing the solvent after the reaction is finished, and purifying to obtain a target product 6;
the structural formula of the compound 1 is as follows:the structural formula of compound 2 is:the structural formula of compound 3 is:the structural formula of compound 4 is:the structural formula of compound 5 is:the structural formula of the target product 6 is as follows:
further, in the step (1), the temperature for stirring the reaction is 75-85 ℃.
Further, in the step (1), the stirring reaction time is 8-10 h.
Further, in the step (2), the reaction time at room temperature is 2.5 h-3.5 h.
Further, in the step (2), the DDQ is added in an ice water bath for reaction for 25-35 min.
The invention also provides a preparation method of the novel spiro pyrrole [2, 1-b ] quinazolinone derivative, which comprises the following steps:
(1) preparation of compound 3: adding the compound 1, the compound 2 and water into a reaction container in sequence, heating, stirring for reaction, after the reaction is finished, performing suction filtration, taking filter residues, washing and drying to obtain a compound 3;
(2) preparation of compound 4': adding dichloromethane and chlorochromate pyridinium into the reaction vessel in sequence, and reacting at low temperature; after the reaction is finished, a compound 4' containing dichloromethane is obtained;
(3) preparation of compound 5': adding a compound 3, p-toluenesulfonic acid, tetrahydrofuran, anhydrous magnesium sulfate and the compound 4 'containing dichloromethane in the step (2) into a reaction container in sequence, reacting at room temperature, adding DDQ into an ice water bath after the reaction is finished, removing the solvent after the reaction is finished, and purifying to obtain a compound 5';
(4) preparing a target product 6: adding the compound 5', palladium acetate, boron trifluoride ether solution and trichloromethane into a reaction vessel in sequence, heating, stirring for reaction, removing the solvent after the reaction is finished, and purifying to obtain a target product 6;
the structural formula of the compound 1 is as follows:the structural formula of compound 2 is:the structural formula of compound 3 is:the structural formula of compound 4' is:the structural formula of compound 5' is:the structural formula of the target product 6 is as follows:
the invention also provides: an application of new spiro pyrrole [2, 1-b ] quinazolinone derivative in preparing antineoplastic medicine is provided.
The invention relates to a preparation route I of a novel spiro pyrrole [2, 1-b ] quinazolinone derivative, which comprises the following steps:
the invention relates to a preparation route II of a novel spiro pyrrole [2, 1-b ] quinazolinone derivative, which comprises the following steps:
the invention synthesizes the new spiro pyrrole [2, 1-b ] quinazolinone derivative by a simple method, has high yield and low production cost, and the obtained new spiro pyrrole [2, 1-b ] quinazolinone derivative has good anticancer effect on different tumor cells, can be prepared into various dosage forms of anticancer drugs, and has high medical value and wide market prospect.
Detailed Description
Any feature disclosed in this specification (including any accompanying claims, abstract) may be replaced by alternative features serving equivalent or similar purposes, unless expressly stated otherwise. That is, unless expressly stated otherwise, each feature is only an example of a generic series of equivalent or similar features.
Example 1: synthesis of Compound 6a
To a 250mL round bottom flask was added isatoic anhydride 2a (5000mg, 30.6mmol), followed by p-anisidine (3774mg, 30.6mmol) and finally water (80mL) with magnetic stirring. The reaction was carried out in an oil bath at 80 ℃ for 9h to precipitate a brown solid. Filtration with suction and drying gave 7405mg (yield 99%) of compound 3a as a brown solid.
To a 150mL round-bottomed flask were added 3a (3000mg, 12.39mmol), p-toluenesulfonic acid (639mg, 3.72mmol), tetrahydrofuran (40.0mL), anhydrous magnesium sulfate (4460mg, 37.17mmol), 3-trimethylsilylpropynaldehyde (1.8mL, 12.39mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (3375mg, 14.87mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:4) to give 3048mg of compound 4a as a pale yellow solid (yield 70%).
To a 100mL round-bottom flask was added sequentially compound 4a (1960mg, 5.6mmol), acetone (25mL) and 1% aqueous silver nitrate (10mL) with magnetic stirring. The reaction was stirred at ambient temperature for 6h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gelPurification by chromatography (eluent: V)EA:VPE1:6, 1:4, 1:1) to give compound 5a as a pale yellow solid 1098mg (71%).
To a 10mL round-bottom flask, compound 5a (80mg, 0.29mmol), palladium acetate (6.5mg, 0.029mmol) and finally a 1.0mmol/mL boron trifluoride etherate solution (1.45mL, 1.45mmol) prepared using chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (4mL) was added. Reaction in an oil bath at 60 ℃ for 3h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1) to give compound 6a as a pale yellow solid, 70mg (yield 92%).
1H NMR(400MHz,CDCl3)8.26(d,J=7.8Hz,1H),7.84–7.71(m,2H),7.51(t,J=7.3Hz,1H),6.87(d,J=5.8Hz,1H),6.66–6.49(m,5H).13C NMR(100MHz,CDCl3)184.0,159.2,156.9,148.9,143.7,141.9,134.8,132.4,129.1,127.7,127.4,126.7,120.9,69.1.
Example 2: synthesis of Compound 6b
To a 250mL round bottom flask, 2b (2500mg, 14.1mmol) was added with magnetic stirring, followed by p-anisidine (1735mg, 14.1mmol) and finally water (80 mL). The reaction was carried out in an oil bath at 80 ℃ for 9h to precipitate a brown solid. Suction filtration and drying gave 3400mg (94% yield) of compound 3b as a brown solid.
Under electromagnetic stirring and cooling in an ice-water bath, 3b (2000mg, 7.8mmol), p-toluenesulfonic acid (402mg, 2.3mmol), tetrahydrofuran (40.0mL), anhydrous magnesium sulfate (2808mg, 23.4mmol), 3-trimethylsilylpropynaldehyde (1.1mL, 7.8mmol) were added in this order to a 150mL round-bottomed flask, the mixture was reacted at room temperature for 3 hours, DDQ (2124mg, 9.4mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was subjected to column chromatographyPurification (eluent: V)EA:VPE1.88mg of compound 4b was obtained as a pale yellow solid (yield 67%).
To a 100mL round-bottomed flask, compound 4b (1880mg, 5.2mmol), acetone (25mL) and 1% aqueous silver nitrate (9mL) were added in that order with magnetic stirring. The reaction was stirred at ambient temperature for 6h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:6, 1:4, 1:1) to give 1070mg (yield 71%) of compound 5b as a pale yellow solid.
To a 10mL round bottom flask, compound 5b (150mg, 0.52mmol), palladium acetate (12mg, 0.052mmol) were added under magnetic stirring, followed by 1.0mmol/mL boron trifluoride etherate (2.6mL, 2.6mmol) in chloroform as a solvent, and followed by chloroform (4 mL). Reaction in an oil bath at 60 ℃ for 3h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1) to give compound 6b as a pale yellow solid, 105mg (74% yield).
1H NMR(400MHz,CDCl3)7.64–7.54(m,2H),7.24(d,J=6.8Hz,1H),6.81(d,J=5.8Hz,1H),6.62–6.53(m,4H),6.51(d,J=5.8Hz,1H),2.83(s,3H).13C NMR(100MHz,CDCl3)184.0,159.9,156.5,150.7,143.6,142.5,141.7,133.9,132.2,130.2,128.9,126.0,119.3,69.3,23.1.
Example 3: synthesis of Compound 6c
Under the conditions of electromagnetic stirring and ice-water bath cooling, 1c (2000mg, 11.6mmol) and tetrahydrofuran (35mL) are respectively added into a 150mL round-bottom flask, and after the reaction system is cooled, triphosgene is slowly added(1172mg,3.9 mmol). In N2The reaction was stirred for 6h under protection. After the reaction was completed, the solvent was removed under reduced pressure, and an appropriate amount of petroleum ether was added thereto and subjected to ultrasonic treatment to thereby suspend the precipitated solid in petroleum ether sufficiently, followed by suction filtration and drying to obtain 1790mg (78%) of a white solid of Compound 2 c.
To a 250mL round bottom flask, 2c (1790mg, 9.1mmol) was added with magnetic stirring, followed by p-anisidine (1115mg, 9.1mmol) and finally water (80 mL). The reaction was carried out in an oil bath at 80 ℃ for 6h, and a white solid precipitated. Filtration with suction and drying gave 1020mg (41% yield) of compound 3c as a white solid.
To a 150mL round-bottomed flask were added 3c (1020mg, 3.7mmol), p-toluenesulfonic acid (190mg, 1.1mmol), tetrahydrofuran (40.0mL), anhydrous magnesium sulfate (1328mg, 11.1mmol), 3-trimethylsilylpropyraldehyde (0.55mL, 3.7mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (1005mg, 4.4mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the reaction was terminated, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:4) to yield 600mg of compound 4c as a pale yellow solid (43% yield).
To a 100mL round-bottomed flask, compound 4c (600mg, 1.6mmol), acetone (25mL) and 1% aqueous silver nitrate (3mL) were added in that order with magnetic stirring. The reaction was stirred at room temperature for 4h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:1) to give compound 5c as a white solid, 430mg (88% yield).
To a 10mL round-bottom flask, compound 5c (200mg,0.64mmol), palladium acetate (15mg, 0.064mmol) and finally a 1.0mmol/mL boron trifluoride etherate solution (3.3mL, 3.3mmol) prepared using chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (4mL) was added. Reaction in an oil bath at 60 ℃ for 3h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, and the mixture was extracted with dichloromethane (4 × 10mL), and the mixture was combinedThe organic phase is freed of the solvent under reduced pressure and the crude product is purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:2, 1:1) to give 103mg (yield 54%) of compound 6c as a pale yellow solid.
1H NMR(400MHz,CDCl3)7.65–7.61(m,2H),7.49–7.46(m,1H),6.81(d,J=5.8Hz,1H),6.61–6.55(m,3H),6.55–6.50(m,2H).13C NMR(100MHz,CDCl3)183.9,157.3,157.3,151.6,144.7,141.6,134.7,134.2,132.6,130.2,128.7,127.1,118.0,69.5.
Example 4: synthesis of Compound 6d
1d (2000mg, 10.15mmol) and tetrahydrofuran (35mL) were added to a 150mL round-bottomed flask under electromagnetic stirring and cooling in an ice-water bath, and after the reaction system had cooled, triphosgene (1021mg, 3.45mmol) was slowly added. In N2Stirring for reaction for 5h under protection. After the reaction was completed, the solvent was removed under reduced pressure, and an appropriate amount of petroleum ether was added thereto and subjected to ultrasonic treatment to thereby suspend the precipitated solid in petroleum ether sufficiently, followed by suction filtration and drying to obtain 2230mg (yield 99%) of a brown solid of Compound 2 d.
To a 250mL round bottom flask, 2d (2140mg, 10.85mmol) was added with magnetic stirring, followed by p-anisidine (1335mg, 10.85mmol) and finally water (90 mL). The reaction was carried out in an oil bath at 80 ℃ for 7h, a brown solid precipitated. Suction filtration and drying gave 2230mg (70% yield) of Compound 3d as a brown solid.
To a 150mL round bottom flask were added 3d (1500mg, 4.96mmol), p-toluenesulfonic acid (256mg, 1.78mmol), tetrahydrofuran (40.0mL), anhydrous magnesium sulfate (1786mg, 14.88mmol), 3-trimethylsilylpropynaldehyde (0.71mL, 4.96mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3h, DDQ (1351mg, 5.95mmol) was added in an ice-water bath, the reaction was carried out for 30 min, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10) to give 1500mg of compound 4d as a pale yellow solid (yield 74%).
To a 100mL round-bottomed flask, compound 4d (1500mg, 3.67mmol), acetone (20mL) and 1% aqueous silver nitrate solution (6.6mL) were added sequentially with magnetic stirring. The reaction was stirred at room temperature for 4h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:1) to give compound 5d as a white solid 450mg (37% yield).
To a 10mL round-bottom flask, compound 5d (50mg,0.15mmol), palladium acetate (3.5mg, 0.015mmol) and finally a 1.0mmol/mL boron trifluoride etherate solution (0.74mL, 0.74mmol) prepared using chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (4mL) was added. Reaction in an oil bath at 60 ℃ for 3h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1) to give 45mg of compound 6d as a pale yellow solid (yield 94%).
1H NMR(400MHz,CDCl3)7.58(s,1H),7.14(s,1H),6.82(d,J=5.8Hz,1H),6.63–6.51(m,5H),4.01(s,3H),3.96(s,3H).13C NMR(100MHz,CDCl3)184.1,158.8,155.8,155.2,149.4,145.1,142.6,142.1,132.3,129.1,114.1,108.1,105.5,69.0,56.4,56.3.
Example 5: synthesis of Compound 6e
To a 250mL round bottom flask, 2e (2000mg, 10.36mmol) was added with magnetic stirring, followed by p-anisidine (1275mg, 10.36mmol) and finally water (80 mL). The reaction was carried out in an oil bath at 80 ℃ for 7h, and a white solid precipitated. Filtration with suction and drying gave 2100mg (75% yield) of compound 3e as a white solid.
To a 150mL round bottom flask with an electromagnetic stirring barTo this mixture were added 3e (2100mg, 5.50mmol), p-toluenesulfonic acid (284mg, 1.65mmol), tetrahydrofuran (40.0mL), anhydrous magnesium sulfate (1980mg, 16.50mmol), 3-trimethylsilylpropynaldehyde (0.81mL, 5.50mmol) in this order, the mixture was reacted at room temperature for 3 hours, DDQ (1498mg, 6.60mmol) was added under an ice-water bath, the reaction was terminated, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:6) to yield 975mg of compound 4e as a pale yellow solid (47% yield).
To a 100mL round-bottomed flask, compound 4e (970mg, 2.56mmol), acetone (20mL) and 1% aqueous silver nitrate (4.6mL) were added sequentially with magnetic stirring. The reaction was stirred at room temperature for 5h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:1) to give compound 5e as a white solid 700mg (89% yield).
To a 10mL round-bottom flask, compound 5e (200mg,0.65mmol), palladium acetate (14.6mg, 0.065mmol) and finally a 1.0mmol/mL boron trifluoride etherate solution (3.25mL, 3.25mmol) prepared using chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (3mL) was added. Reaction in an oil bath at 60 ℃ for 2h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give compound 6e as a pale yellow solid, 152mg (yield 80%).
1H NMR(400MHz,CDCl3)7.65(d,J=8.9Hz,1H),7.60(d,J=2.9Hz,1H),7.35(dd,J=8.9,3.0Hz,1H),6.83(d,J=5.8Hz,1H),6.61–6.49(m,5H),3.87(s,3H).13C NMR(100MHz,CDCl3)184.0,159.1,158.8,154.9,143.3,142.3,142.0,132.3,129.2,129.1,124.7,121.7,106.3,68.9,55.8.
Example 6: synthesis of Compound 6f
1f (2000mg, 13.23mmol) and tetrahydrofuran (35mL) were added to a 150mL round-bottomed flask under magnetic stirring and cooling in an ice-water bath, and after the reaction system had cooled, triphosgene (1335mg, 4.49mmol) was slowly added. In N2Stirring for reaction for 5h under protection. After the reaction, the solvent was removed under reduced pressure, and a suitable amount of petroleum ether was added thereto and subjected to ultrasonic treatment to thereby suspend the precipitated solid in petroleum ether sufficiently, followed by suction filtration and drying to obtain 2320mg (yield 99%) of a white solid of Compound 2 f.
To a 250mL round bottom flask, 2f (2300mg, 13.00mmol) was added with magnetic stirring, followed by p-anisidine (1599mg, 13.00mmol) and finally water (100 mL). The reaction was carried out in an oil bath at 80 ℃ for 8h to precipitate a pale yellow solid. Suction filtration and drying gave 2750mg (83% yield) of compound 3f as a pale yellow solid.
To a 150mL round-bottomed flask were added 3f (2700mg, 10.50mmol), p-toluenesulfonic acid (541mg, 3.15mmol), tetrahydrofuran (40.0mL), anhydrous magnesium sulfate (3780mg, 31.5mmol), 3-trimethylsilylpropynaldehyde (1.6mL, 10.50mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (2860mg, 12.60mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10) to give 3000mg of compound 4f as a pale yellow solid (yield 79%).
To a 100mL round-bottomed flask, compound 4f (760mg, 2.10mmol), acetone (15mL) and 1% aqueous silver nitrate solution (3.7mL) were added sequentially with magnetic stirring. The reaction was stirred at room temperature for 4h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:1) to give compound 5f as a white solid 510mg (95% yield).
To a 10mL round bottom flask, add the compound with magnetic stirring5f (100mg,0.34mmol), palladium acetate (7.6mg, 0.034mmol), and finally, 1.0mmol/mL of boron trifluoride etherate (1.70mL, 1.70mmol) prepared using chloroform as a solvent, and finally, chloroform (4mL) were added. Reaction in an oil bath at 60 ℃ for 2h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1) to give compound 6f as a pale yellow solid 76mg (yield 80%).
1H NMR(400MHz,CDCl3)8.01(s,1H),7.63–7.60(m,2H),6.83(d,J=5.8Hz,1H),6.61–6.49(m,5H),2.47(s,3H).13C NMR(100MHz,CDCl3)184.1,159.2,156.1,146.9,143.1,142.1,137.8,136.2,132.3,129.2,127.4,126.1,120.6,69.0,21.4.
Example 7: synthesis of Compound 6g
To a 150mL round bottom flask, 2g (2000mg, 11.00mmol) was added with magnetic stirring, followed by p-anisidine (1353mg, 11.00mmol) and finally water (60 mL). The reaction was carried out in an oil bath at 80 ℃ for 6h, and a white solid precipitated. Suction filtration and drying gave compound 3g of 2400mg (84% yield) as a white solid.
To a 150mL round-bottomed flask were added 3g (2400mg, 9.23mmol), p-toluenesulfonic acid (476mg, 2.77mol), tetrahydrofuran (50.0mL), anhydrous magnesium sulfate (3322mg, 27.69mmol), 3-trimethylsilylpropynaldehyde (1.36mL, 9.23mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (2514mg, 11.08mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:4) to give 1290mg of compound 4g as a pale yellow solid (38% yield).
To a 100mL round bottom flask was added sequentially 4g of compound (1290mg, 3.52 mm) with magnetic stirringol), acetone (20mL) and 1% aqueous silver nitrate solution (6.3 mL). The reaction was stirred at room temperature for 5h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:1) to give compound 5g as a white solid 820mg (yield 79%).
To a 10mL round-bottom flask, 5g (200mg,0.68mmol) of the compound, palladium acetate (15.3mg, 0.068mmol) and finally a 1.0mmol/mL boron trifluoride ether solution (3.40mL, 3.40mmol) prepared using chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (3mL) was added. Reaction in an oil bath at 60 ℃ for 2h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give compound 6g as a pale yellow solid 140mg (yield 74%).
1H NMR(400MHz,CDCl3)8.27–8.23(m,1H),7.38(dd,J=9.6,2.4Hz,1H),7.23–7.18(m,1H),6.85(d,J=5.8Hz,1H),6.65–6.56(m,3H),6.56–6.49(m,2H).13C NMR(100MHz,CDCl3)183.8,166.7(J=253.6Hz),158.4,158.0,151.3(J=13.0Hz),144.5,141.5,132.5,129.3(J=10.7Hz),129.0,117.6(J=2.1Hz),116.0(J=23.4Hz),113.2(J=22.0Hz),69.1.
Example 8: synthesis of Compound 6h
To a 150mL round bottom flask was added 2h (2000mg, 10.10mmol) with magnetic stirring, followed by p-anisidine (1245mg, 10.10mmol) and finally water (60 mL). The reaction was carried out in an oil bath at 80 ℃ for 6h, a brown solid precipitated. Filtration with suction and drying gave compound (3 h) as a brown solid (2420 mg, 87% yield).
Under an electromagnetic stirring bar, the mixture is sintered to a round bottom of 150mL3h (2400mg, 8.69mmol), p-toluenesulfonic acid (448mg, 2.61mol), tetrahydrofuran (50.0mL), anhydrous magnesium sulfate (3128mg, 26.07mmol), 3-trimethylsilylpropynaldehyde (1.28mL, 8.69mmol) were added to the flask in this order, the mixture was reacted at room temperature for 3h, DDQ (2367mg, 10.07mmol) was added to the mixture in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:6) to give 1500mg of compound 4h as a pale yellow solid (44% yield).
To a 100mL round bottom flask was added compound 4h (1500mg, 3.92mmol), acetone (20mL) and 1% aqueous silver nitrate (7.0mL) in that order with magnetic stirring. The reaction was stirred at room temperature for 5h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:1) to give compound 5h as 825mg (68% yield) as a pale yellow solid.
To a 10mL round bottom flask, compound 5h (150mg,0.48mmol), palladium acetate (11mg, 0.048mmol) and finally a 1.0mmol/mL boron trifluoride etherate solution (2.40mL, 2.40mmol) in chloroform as solvent were added with magnetic stirring and finally chloroform (4 mL). Reaction in an oil bath at 60 ℃ for 2h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give 127mg of compound 6h as a pale yellow solid (yield 89%).
1H NMR(400MHz,CDCl3)8.19(d,J=2.3Hz,1H),7.74–7.67(m,2H),6.86(d,J=5.8Hz,1H),6.64–6.58(m,3H),6.55–6.50(m,2H).13C NMR(100MHz,CDCl3)183.8,158.0,157.0,147.5,144.0,141.4,135.2,133.2,132.6,129.2,129.0,126.1,122.0,69.2.
Example 9: synthesis of Compound 6i
To a 150mL round bottom flask, 2i (1170mg, 4.87mmol) was added, followed by p-anisidine (600mg, 4.87mmol) and finally water (40mL) with magnetic stirring. The reaction was carried out in an oil bath at 80 ℃ for 6h, a brown solid precipitated. Suction filtration and drying gave 1170mg (75% yield) of Compound 3i as a brown solid.
To a 150mL round-bottomed flask were added 3i (1170mg, 3.65mmol), p-toluenesulfonic acid (188mg, 1.05mol), tetrahydrofuran (20.0mL), anhydrous magnesium sulfate (1314mg, 10.95mmol), 3-trimethylsilylpropenal (0.53mL, 3.65mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (994mg, 4.38mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the reaction was terminated, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10) to give 1010mg of compound 4i as a pale yellow solid (yield 65%).
To a 100mL round-bottomed flask, compound 4i (1000mg, 2.34mmol), acetone (20mL) and 1% aqueous silver nitrate solution (7.0mL) were added sequentially with magnetic stirring. The reaction was stirred at ambient temperature for 6h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:1) to give compound 5i as a pale yellow solid, 800mg (97% yield).
To a 10mL round-bottom flask, compound 5i (100mg,0.28mmol), palladium acetate (6mg, 0.028mmol) and finally a 1.0mmol/mL boron trifluoride etherate solution (1.40mL, 1.40mmol) prepared using chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (5mL) was added. Reaction in an oil bath at 60 ℃ for 2h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE=1:4,1:2,1:1, 2:1) to give 77mg (yield 80%) of compound 6i as a pale yellow solid.
1H NMR(400MHz,CDCl3)8.34(d,J=2.3Hz,1H),7.86–7.84(m,1H),7.61–7.59(m,1H),6.84(d,J=5.8Hz,1H),6.63–6.57(m,3H),6.54–6.49(m,2H).13C NMR(100MHz,CDCl3)183.8,157.9,157.2,147.8,144.1,141.4,137.9,132.6,129.4,129.3,129.0,122.3,120.9,69.2.
Example 10: synthesis of Compound 6j
1j (2000mg, 11.96mmol) and tetrahydrofuran (35mL) were added to a 150mL round-bottomed flask under electromagnetic stirring and cooling in an ice-water bath, and after the reaction system had cooled, triphosgene (1204mg, 4.07mmol) was slowly added. In N2Stirring for reaction for 6h under protection. After the reaction, the solvent was removed under reduced pressure, and a suitable amount of petroleum ether was added thereto and subjected to ultrasonic treatment to sufficiently suspend the precipitated solid in petroleum ether, followed by suction filtration and drying to obtain 2250mg (yield: 97%) of a brown solid of compound 2 j.
To a 250mL round bottom flask, 2j (2250mg, 11.65mmol), additional p-anisidine (1550mg, 11.65mmol), and finally water (80mL) were added with magnetic stirring. The reaction was carried out in an oil bath at 80 ℃ for 8h, a brown solid precipitated. Suction filtration and drying gave 2470mg (78% yield) of compound 3j as a brown solid.
To a 150mL round-bottomed flask were added 3j (1500mg, 5.50mmol), p-toluenesulfonic acid (283mg, 1.65mmol), tetrahydrofuran (40.0mL), anhydrous magnesium sulfate (1980mg, 16.50mmol), 3-trimethylsilylpropynaldehyde (0.81mL, 5.50mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (1498mg, 6.60mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10) to yield 1930mg of compound 4j as a pale yellow solid (93% yield).
To a 50mL round bottom flask was added compound 4j (650mg,1.72mmol), acetone (15mL) and 1% aqueous silver nitrate (3 mL). The reaction was stirred at room temperature for 4h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:1) to give 400mg of compound 5j as a white solid (yield 76%).
To a 10mL round-bottom flask, compound 5j (150mg,0.49mmol), palladium acetate (11mg, 0.049mmol) and finally a 1.0mmol/mL boron trifluoride etherate solution (2.45mL, 2.45mmol) prepared using chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (4mL) was added. Reaction in an oil bath at 60 ℃ for 2h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1) to give 102mg (yield 72%) of compound 6j as a pale yellow solid.
1H NMR(400MHz,CDCl3)8.13(d,J=8.8Hz,1H),7.12–7.11(m,1H),7.05(dd,J=8.8,2.4Hz,1H),6.82(d,J=5.8Hz,1H),6.63–6.46(m,5H),3.92(s,3H).13C NMR(100MHz,CDCl3)184.0,164.9,158.8,157.5,151.3,143.9,142.1,132.3,129.1,128.1,117.0,114.3,108.8,69.0,55.8.
Example 11: synthesis of Compound 6k
1j (2000mg, 13.23mmol) and tetrahydrofuran (45mL) were added to a 150mL round-bottomed flask under electromagnetic stirring and cooling in an ice-water bath, and after the reaction system had cooled, triphosgene (1335mg, 4.49mmol) was slowly added. In N2Stirring for reaction for 5h under protection. After the reaction, the solvent was removed under reduced pressure, and a suitable amount of petroleum ether was added thereto and subjected to ultrasonic treatment to thereby suspend the precipitated solid in petroleum ether sufficiently, followed by suction filtration and drying to obtain 2170mg (yield) of a gray solid of Compound 2k93%)。
To a 250mL round bottom flask, 2k (2170mg, 12.25mmol) was added with magnetic stirring, followed by p-anisidine (1507mg, 12.25mmol) and finally water (80 mL). The reaction was carried out in an oil bath at 80 ℃ for 8h, a grey solid precipitated. Filtration with suction and drying gave 2350mg (75% yield) of compound 3k as a grey solid.
To a 150mL round bottom flask were added 3k (2350mg, 9.18mmol), p-toluenesulfonic acid (473mg, 2.75mmol), tetrahydrofuran (40.0mL), anhydrous magnesium sulfate (3304mg, 27.54mmol), 3-trimethylsilylpropynaldehyde (1.30mL, 9.18mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3h, DDQ (2500mg, 11.02mol) was added in an ice-water bath, the reaction was carried out for 30 min, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10) to give 3000mg of compound 4k as a pale yellow solid (yield 90%).
To a 50mL round bottom flask was added sequentially compound 4k (960mg, 2.65mmol), acetone (15mL) and 1% aqueous silver nitrate (5mL) with magnetic stirring. The reaction was stirred at room temperature for 4h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:1) to give 526mg of compound 5k as a white solid (yield 68%).
To a 10mL round bottom flask, compound 5k (150mg,0.51mmol), palladium acetate (11.5mg, 0.051mmol) was added under magnetic stirring, and finally, a 1.0mmol/mL boron trifluoride etherate solution (2.60mL, 2.60mmol) prepared using chloroform as a solvent was added, and finally, chloroform (4mL) was added. Reaction in an oil bath at 60 ℃ for 2h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give 122mg (yield 86%) of compound 6k as a pale yellow solid.
1H NMR(400MHz,CDCl3)8.11(d,J=8.1Hz,1H),7.51(s,1H),7.30(dd,J=8.1,1.0Hz,1H),6.83(d,J=5.8Hz,1H),6.60–6.50(m,5H),2.51(s,3H).13C NMR(100MHz,CDCl3)184.0,159.1,156.9,149.1,145.9,143.5,142.1,132.3,129.2,128.9,127.5,126.4,118.4,69.0,22.0.
Example 12: synthesis of Compound 6l
1l (2000mg, 12.89mmol) of tetrahydrofuran (45mL) was added to a 150mL round-bottomed flask under magnetic stirring and cooling in an ice-water bath, and after the reaction system had cooled, triphosgene (1300mg, 4.38mmol) was slowly added. In N2Stirring for reaction for 5h under protection. After the reaction, the solvent was removed under reduced pressure, and a suitable amount of petroleum ether was added thereto and subjected to ultrasonic treatment to thereby suspend the precipitated solid in petroleum ether sufficiently, followed by suction filtration and drying to obtain 2260mg (yield 97%) of 2l of a white solid as a compound.
To a 250mL round bottom flask, 2l (2260mg, 12.48mmol) was added with magnetic stirring, followed by p-anisidine (1536mg, 12.48mmol) and finally water (80 mL). The reaction was carried out in an oil bath at 80 ℃ for 7h, a brown solid precipitated. Suction filtration and drying gave 2560mg (yield 79%) of compound 3l as a brown solid.
To a 150mL round bottom flask were added 3l (1500mg, 5.76mmol), p-toluenesulfonic acid (297mg, 1.73mmol), tetrahydrofuran (30.0mL), anhydrous magnesium sulfate (2070mg, 17.28mmol), 3-trimethylsilylpropynaldehyde (0.85mL, 5.76mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (1569mg, 6.91mol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the reaction was terminated, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:10,1:6) to give 2040mg of compound 4l as a pale yellow solid (yield 97%).
To a 100mL round-bottomed flask, 4l of compound (2000mg, 5.46mmol), acetone (30mL) and 1% aqueous silver nitrate solution (9.8mL) were added sequentially with magnetic stirring. Stirring and reacting for 6h at normal temperature under the condition of keeping out of The Light (TLC)Monitoring the reaction VEA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:6, 1:4, 1:2) to give 560mg of compound 5l as a white solid (yield 35%).
To a 10mL round-bottomed flask, 5l of the compound (80mg,0.27mmol), palladium acetate (6.1mg, 0.027mmol) and finally a boron trifluoride ether solution (1.36mL, 1.36mmol) formulated in chloroform as a solvent were added, and finally chloroform (5mL) was added, with electromagnetic stirring. Reaction in an oil bath at 60 ℃ for 3h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give 65mg (yield 87%) of compound 6l as a pale yellow solid.
1H NMR(400MHz,CDCl3)7.86(dd,J=8.3,2.9Hz,1H),7.75–7.72(m,1H),7.53–7.46(m,1H),6.84(d,J=5.8Hz,1H),6.62–6.55(m,3H),6.54–6.51(m,2H).13C NMR(100MHz,CDCl3)183.8,161.2(J=248.3Hz),158.4(J=3.4Hz),156.3(J=2.2Hz),145.6(J=2.1Hz),143.5,141.6,132.5,130.1(J=8.1Hz),129.0,123.2(J=23.9Hz),122.2(J=8.6Hz),111.8(J=23.8Hz),69.0.
Example 13: synthesis of Compound 6m
To a 250mL round bottom flask, 2m (2000mg, 8.30mmol) was added with magnetic stirring, followed by p-anisidine (1021mg, 8.30mmol), and finally water (80 mL). The reaction was carried out in an oil bath at 80 ℃ for 6h, and a white solid precipitated. Suction filtration and drying were carried out to obtain 1270mg (48% yield) of compound 3m as a white solid.
To a 150mL round-bottomed flask were added 3m (1270mg, 3.96mmol), p-toluenesulfonic acid (204mg, 1.19mol) in this order with electromagnetic stirring,tetrahydrofuran (30.0mL), anhydrous magnesium sulfate (1425mg, 11.88mmol), 3-trimethylsilylpropylaldehyde (0.57mL, 3.96mmol), the mixture was reacted at room temperature for 3h, DDQ (1078mg, 4.75mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:4) to yield 851mg of compound 4m as a pale yellow solid (51% yield).
To a 100mL round-bottomed flask, compound 4m (850mg, 1.99mmol), acetone (15mL) and 1% aqueous silver nitrate solution (4mL) were added in that order with magnetic stirring. The reaction was stirred at room temperature for 5h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:2) to give 435mg of compound 5m as a white solid (yield 62%).
To a 10mL round bottom flask, compound 5m (100mg,0.28mmol), palladium acetate (6.3mg, 0.028mmol) and finally boron trifluoride etherate (1.40mL, 1.40mmol) in 1.0mmol/mL prepared using chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (5mL) was added. Reaction in an oil bath at 60 ℃ for 2h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give 79mg (yield 82%) of compound 6m as a pale yellow solid.
1H NMR(400MHz,CDCl3)8.09(d,J=8.5Hz,1H),7.91(d,J=1.8Hz,1H),7.61(dd,J=8.5,1.9Hz,1H),6.86(d,J=5.8Hz,1H),6.65–6.58(m,3H),6.55–6.50(m,2H).13C NMR(100MHz,CDCl3)183.8,158.6,157.9,150.0,144.4,141.4,132.6,130.7,130.4,129.5,129.0,128.0,119.7,69.2.
Example 14: synthesis of Compound 6n
1n (2000mg, 9.70mmol) and tetrahydrofuran (45mL) were added to a 150mL round-bottomed flask under magnetic stirring and cooling in an ice-water bath, and after the reaction system had cooled, triphosgene (984mg, 3.32mmol) was slowly added. In N2Stirring for reaction for 5h under protection. After the reaction was completed, the solvent was removed under reduced pressure, and an appropriate amount of petroleum ether was added thereto and subjected to ultrasonic treatment to thereby suspend the precipitated solid in petroleum ether sufficiently, followed by suction filtration and drying to obtain 2200mg (yield 98%) of a white solid of Compound 2 n.
To a 250mL round bottom flask, 2n (2200mg, 9.52mmol) was added with magnetic stirring, followed by p-anisidine (1171mg, 9.52mol) and finally water (80 mL). The reaction was carried out in an oil bath at 80 ℃ for 8h, a brown solid precipitated. Suction filtration and drying gave 2530mg (86% yield) of compound 3n as a brown solid.
To a 150mL round-bottomed flask were added 3n (1500mg, 4.80mmol), p-toluenesulfonic acid (247mg, 1.44mmol), tetrahydrofuran (30.0mL), anhydrous magnesium sulfate (1728mg, 14.4mmol), 3-trimethylsilylpropynaldehyde (0.71mL, 4.80mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (1307mg, 5.76mol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:10,1:4) to give 1714mg of compound 4n as a pale yellow solid (86% yield).
To a 100mL round-bottomed flask, compound 4n (1714mg, 4.12mmol), acetone (30mL) and 1% aqueous silver nitrate (7.4mL) were added sequentially with magnetic stirring. The reaction was stirred at ambient temperature for 6h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:6, 1:4, 1:1) to give 1130mg of compound 5n as a white solid (yield 80%).
To a 10mL round bottom flask, compound 5n (150mg,0.44mmol), palladium acetate (9.8mg, 0.044mmol) were added under magnetic stirring, and finally chloroform was added as a solvent1.0mmol/mL boron trifluoride in diethyl ether (2.18mL, 2.18mmol) was prepared and chloroform (5mL) was added last. Reaction in an oil bath at 60 ℃ for 2h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give 125mg (yield 87%) of compound 6n as a pale yellow solid.
1H NMR(400MHz,CDCl3)8.37(d,J=8.3Hz,1H),8.02(s,1H),7.71(d,J=8.2Hz,1H),6.89(d,J=5.8Hz,1H),6.68(d,J=5.8Hz,1H),6.64–6.61(m,2H),6.55–6.52(m,2H).13C NMR(100MHz,CDCl3)183.7,158.2,158.0,149.1,144.7,141.1,136.3(J=65.6Hz),132.7,128.9,127.8,125.2(J=8.0Hz),123.4(J=6.9Hz),123.3(J=271.4Hz),123.2,69.2.
Example 15: synthesis of Compound 6o
Under the conditions of electromagnetic stirring and cooling in an ice-water bath, 1o (2000mg, 10.98mmol) and tetrahydrofuran (45mL) were added to a 150mL round-bottomed flask, and after the reaction system had cooled, triphosgene (1104mg, 3.73mmol) was slowly added. In N2Stirring for reaction for 5h under protection. After the reaction, the solvent was removed under reduced pressure, and a suitable amount of petroleum ether was added thereto and subjected to ultrasonic treatment to thereby suspend the precipitated solid in petroleum ether sufficiently, followed by suction filtration and drying to obtain 2000mg (yield: 88%) of compound 2o as a yellow solid.
To a 250mL round bottom flask, 2o (2000mg, 9.60mmol) was added with magnetic stirring, followed by p-anisidine (1180mg, 9.60mol) and finally water (80 mL). The reaction was carried out in an oil bath at 80 ℃ for 8h, and a yellow solid precipitated. Suction filtration and drying gave 2200mg (80% yield) of compound 3o as a yellow solid.
To a 150mL round bottom flask were added 3o (2200mg, 7.66mmol), p-toluenesulfonic acid (395mg, 1.40mmol), tetrahydrofuran (30.0mL) sequentially with electromagnetic stirring,anhydrous magnesium sulfate (2758mg, 22.98mmol), 3-trimethylsilylpropenal (1.13mL, 7.66mmol), the mixture was reacted at room temperature for 3 hours, DDQ (2086mg, 9.19mol) was added under an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:10,1:6) to yield 1650mg of compound 4o as a yellow solid (56% yield).
To a 100mL round bottom flask was added sequentially compound 4o (1650mg, 4.20mmol), acetone (30mL) and 1% aqueous silver nitrate (7.5mL) with magnetic stirring. The reaction was stirred at ambient temperature for 6h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:6, 1:4, 1:2) to give 1300mg (96% yield) of compound 5o as a yellow solid.
To a 10mL round bottom flask, compound 5o (150mg,0.47mmol), palladium acetate (10.6mg, 0.047mmol) and finally a 1.0mmol/mL boron trifluoride etherate solution (2.35mL, 2.35mmol) prepared using chloroform as a solvent were added under magnetic stirring, and finally chloroform (4mL) was added. Reaction in an oil bath at 60 ℃ for 3h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give compound 6o as a brown solid 105mg (73% yield).
1H NMR(400MHz,CDCl3)8.55(d,J=2.1Hz,1H),8.41(d,J=8.7Hz,1H),8.25(dd,J=8.7,2.2Hz,1H),6.91(d,J=5.8Hz,1H),6.73(d,J=5.8Hz,1H),6.65–6.62(m,2H),6.55–6.52(m,2H).13C NMR(100MHz,CDCl3)183.6,158.8,157.8,151.8,149.7,145.3,140.6,132.9,128.8,128.5,125.0,123.2,121.0,69.4.
Example 16: synthesis of Compound 6p
To a 250mL round bottom flask, 2p (2500mg, 14.10mmol) was added with magnetic stirring, followed by p-anisidine (1735mg, 14.10mmol) and finally water (80 mL). The reaction was carried out in an oil bath at 80 ℃ for 6h, a grey solid precipitated. Filtration with suction and drying gave 2870mg (80% yield) of compound 3p as a gray solid.
To a 150mL round-bottomed flask were added 3p (2500mg, 9.70mmol), p-toluenesulfonic acid (500mg, 2.91mol), tetrahydrofuran (30.0mL), anhydrous magnesium sulfate (3492mg, 29.10mmol), 3-trimethylsilylpropynaldehyde (1.4mL, 9.70mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (2642mg, 11.64mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:4) to give 2580mg of compound 4p as a pale yellow solid (73% yield).
To a 100mL round-bottomed flask, compound 4p (2580mg, 7.12mmol), acetone (25mL) and 1% aqueous silver nitrate solution (12.7mL) were added sequentially with magnetic stirring. The reaction was stirred at room temperature for 8h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:4, 1:2) to give compound 5p as a white solid 870mg (42% yield).
To a 10mL round-bottom flask, compound 5p (150mg,0.51mmol), palladium acetate (11.5mg, 0.051mmol) were added under magnetic stirring, and finally, a 1.0mmol/mL boron trifluoride etherate solution (2.60mL, 2.60mmol) prepared using chloroform as a solvent was added, and finally, chloroform (4mL) was added. Reaction in an oil bath at 60 ℃ for 4h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give 111mg of compound 6p as a pale yellow solid (yield)78%)。
1H NMR(400MHz,CDCl3)8.10(dd,J=7.9,0.9Hz,1H),7.64–7.62(m,1H),7.38(t,J=7.6Hz,1H),6.90(d,J=5.8Hz,1H),6.61–6.49(m,5H).13C NMR(100MHz,CDCl3)184.0,159.6,155.7,147.6,143.1,142.2,136.3,135.5,132.3,129.5,126.9,124.3,120.8,68.9,17.7.
Example 17: synthesis of Compound 6q
1q (2000mg, 11.65mmol) of tetrahydrofuran (45mL) was added to a 150mL round-bottomed flask under electromagnetic stirring and cooling in an ice-water bath, and after the reaction system had cooled, triphosgene (1172mg, 3.96mmol) was slowly added. In N2Stirring for reaction for 5h under protection. After the reaction, the solvent was removed under reduced pressure, and a suitable amount of petroleum ether was added thereto and subjected to ultrasonic treatment to sufficiently suspend the precipitated solid in petroleum ether, followed by suction filtration and drying to obtain 1570mg (yield 68%) of a yellow solid of compound 2 q.
To a 250mL round bottom flask, 2q (1570mg, 7.94mmol) was added with magnetic stirring, followed by p-anisidine (977mg, 7.94mol) and finally water (60 mL). The reaction was carried out in an oil bath at 80 ℃ for 6h, a brown solid precipitated. Filtration with suction and drying gave 1780mg (81% yield) of compound 3q as a brown solid.
To a 150mL round-bottomed flask were added 3q (1780mg, 6.47mmol), p-toluenesulfonic acid (330mg, 1.94mmol), tetrahydrofuran (30.0mL), anhydrous magnesium sulfate (2300mg, 19.41mmol), 3-trimethylsilylpropynaldehyde (0.96mL, 6.47mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (1760mg, 7.76mol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:10,1:4) to give 1500mg of compound 4q as a yellow solid (61% yield).
To a 100mL round-bottomed flask was added sequentially compound 4q (1500mg, 3.90mmol), acetone (30mL) and 1% aqueous silver nitrate solution (7mL) with magnetic stirring. In the process of avoidingThe reaction was stirred at ambient temperature for 6h under light conditions (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:6, 1:4, 1:2) to give compound 5q as a white solid 1200mg (99% yield).
To a 10mL round-bottomed flask, compound 5q (100mg,0.32mmol), palladium acetate (7.2mg, 0.032mmol) and finally a boron trifluoride ether solution (1.60mL, 1.60mmol) prepared in chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (5mL) was added. Reaction in an oil bath at 60 ℃ for 5h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give 83mg (yield 87%) of compound 6q as a white solid.
1H NMR(400MHz,CDCl3)8.16(dd,J=8.0,1.4Hz,1H),7.86(dd,J=7.8,1.4Hz,1H),7.41(t,J=7.9Hz,1H),6.98(d,J=5.8Hz,1H),6.65–6.58(m,3H),6.53–6.50(m,2H).13C NMR(100MHz,CDCl3)183.8,158.5,157.5,145.7,144.4,141.3,135.2,132.6,132.1,129.32,127.4,125.5,122.5,69.2.
Example 18: synthesis of Compound 6r
To a 250mL round bottom flask, 2r (1500mg, 9.19mmol) was added under magnetic stirring, followed by 3, 4-dimethoxyaniline (1407mg, 9.19mmol) and finally water (60 mL). The reaction was carried out in an oil bath at 80 ℃ for 5h, a brown solid precipitated. Suction filtration and drying gave 2000mg (yield 80%) of compound 3r as a brown solid.
To a 150mL round-bottomed flask were added 3r (1500mg, 5.50mmol), p-toluenesulfonic acid (284mg, 1.65mol), tetrahydrofuran (30.0mL), anhydrous sulfuric acid in that order with electromagnetic stirringMagnesium (1980mg, 16.50mmol), 3-trimethylsilylpropenal (0.80mL, 5.50mmol), the mixture was reacted at room temperature for 3h, DDQ (1498mg, 6.60mmol) was added under ice-water bath, the reaction was terminated for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:4) to give 910mg of compound 4r as a pale yellow solid (yield 44%).
To a 100mL round-bottomed flask, compound 4r (910mg, 2.40mmol), acetone (20mL) and 1% aqueous silver nitrate solution (4.3mL) were added sequentially with magnetic stirring. The reaction was stirred at room temperature for 5h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:6, 1:2) to give compound 5r as a white solid, 500mg (yield 68%).
To a 10mL round bottom flask, compound 5r (150mg,0.49mmol), palladium acetate (11.0mg, 0.049mmol) and finally a 1.0mmol/mL boron trifluoride etherate solution (2.45mL, 2.45mmol) prepared using chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (4mL) was added. Reaction in an oil bath at 30 ℃ for 12h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give compound 6r as a white solid (99 mg, yield 70%).
1H NMR(400MHz,CDCl3)8.24(dd,J=8.0,1.1Hz,1H),7.81–7.73(m,2H),7.55–7.45(m,1H),6.82–6.81(m,1H),6.64–6.55(m,3H),5.40(d,J=2.6Hz,1H),3.70(s,3H).13CNMR(100MHz,CDCl3)179.5,159.0,156.8,153.6,148.9,145.1,142.2,134.7,131.8,128.0,127.6,127.3,126.6,121.1,108.4,70.4,55.4.
Example 19: synthesis of Compound 6s
To a 250mL round bottom flask, 2s (1500mg, 9.19mmol) was added with magnetic stirring, followed by 3-methyl-4-methoxyaniline (1260mg, 9.19mmol) and finally water (60 mL). The reaction was carried out in an oil bath at 80 ℃ for 9h to precipitate a brown solid. Suction filtration and drying gave 2000mg (85% yield) of compound 3s as a brown solid.
To a 150mL round-bottomed flask were added 3s (1100mg, 4.30mmol), p-toluenesulfonic acid (221mg, 1.29mol), tetrahydrofuran (20.0mL), anhydrous magnesium sulfate (1548mg, 12.90mmol), 3-trimethylsilylpropynaldehyde (0.64mL, 4.30mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (1171mg, 5.16mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:4) to give 985mg of compound 4s as a pale yellow solid (63% yield).
To a 100mL round-bottomed flask, compound 4s (985mg, 2.70mmol), acetone (15mL) and 1% aqueous silver nitrate (4.8mL) were added sequentially with magnetic stirring. The reaction was stirred at room temperature for 5h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:6, 1:2) to give 767mg of compound 5s as a white solid (yield 99%).
To a 10mL round bottom flask, compound 5s (100mg,0.35mmol), palladium acetate (7.80mg, 0.035mmol) and finally boron trifluoride etherate (1.70mL, 1.70mmol) in 1.0mmol/mL prepared using chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (5mL) was added. Reaction in an oil bath at 60 ℃ for 3h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give compound 6s as a white solid 84mg (yield)88%)。
1H NMR(400MHz,CDCl3)8.24(dd,J=8.0,1.0Hz,1H),7.79–7.71(m,2H),7.52–7.45(m,1H),6.81(d,J=5.8Hz,1H),6.61–6.48(m,3H),6.29–6.28(m,1H),2.00(d,J=1.4Hz,3H).13C NMR(100MHz,CDCl3)184.8,159.2,157.0,149.0,144.5,141.5,139.6,136.6,134.7,132.1,128.6,127.6,127.3,126.6,121.0,69.6,16.2.
Example 20: synthesis of Compound 6t
To a 250mL round bottom flask, 2t (1500mg, 9.19mmol) was added with magnetic stirring, followed by 3-fluoro-4-methoxyaniline (1297mg, 9.19mmol) and finally water (60 mL). The reaction was carried out in an oil bath at 80 ℃ for 6h, a brown solid precipitated. Suction filtration and drying gave 1450mg (61% yield) of compound 3t as a brown solid.
To a 150mL round bottom flask were added 3t (1450mg, 5.57mmol), p-toluenesulfonic acid (287mg, 1.67mmol), tetrahydrofuran (20.0mL), anhydrous magnesium sulfate (2005mg, 16.71mmol), 3-trimethylsilylpropynaldehyde (0.82mL, 5.57mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3h, DDQ (1517mg, 6.68mmol) was added under ice-water bath, the reaction was carried out for 30 min, the reaction was terminated, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:4) to give 1780mg of compound 4t as a pale yellow solid (87% yield).
To a 100mL round-bottomed flask, compound 4t (1780mg, 4.86mmol), acetone (25mL) and 1% aqueous silver nitrate (8.7mL) were added sequentially with magnetic stirring. The reaction was stirred at room temperature for 5h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:6, 1:2) to give compound 5t as a white solid 620mg (43% yield).
To a 10mL round bottom flask, add under electromagnetic stirringCompound 5s (100mg,0.34mmol), palladium acetate (7.60mg, 0.034mmol), and finally, boron trifluoride etherate (1.70mL, 1.70mmol) prepared in 1.0mmol/mL using chloroform as a solvent, and finally, chloroform (5mL) were added. Reaction in an oil bath at 60 ℃ for 3h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give 39mg (yield 41%) of compound 6t as a pale yellow solid.
1H NMR(400MHz,CDCl3)8.27(dd,J=7.9,1.2Hz,1H),7.81(ddd,J=20.2,13.5,4.4Hz,2H),7.57–7.51(m,1H),6.91(d,J=5.8Hz,1H),6.69–6.60(m,2H),6.57(dd,J=9.9,2.7Hz,1H),6.16(dd,J=10.8,2.7Hz,1H).13C NMR(100MHz,CDCl3)177.1(J=22.0Hz),159.1,156.3,155.6(J=270.0Hz),148.8,142.9(J=2.5Hz),142.6(J=2.4Hz),134.9,131.8(J=4.5Hz),129.4,127.8,127.6,126.7,120.9,118.5(J=16.8Hz),69.9(J=8.7Hz).
Example 21: synthesis of Compound 6u
To a 250mL round bottom flask, 2u (1500mg, 9.19mmol) was added under magnetic stirring, followed by 2-methyl-4-methoxyaniline (1260mg, 9.19mmol) and finally water (60 mL). The reaction was carried out in an oil bath at 80 ℃ for 6h, a brown solid precipitated. Suction filtration and drying gave compound 3u as a brown solid 1610mg (yield 68%).
To a 150mL round-bottomed flask were added 3u (1000mg, 3.90mmol), p-toluenesulfonic acid (201mg, 1.17mmol), tetrahydrofuran (20.0mL), anhydrous magnesium sulfate (1404mg, 11.70mmol), 3-trimethylsilylpropynaldehyde (0.58mL, 3.90mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3h, DDQ (1062mg, 4.68mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the reaction was terminated, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10) to give 847mg of compound 4u as a pale yellow solid (yield 60%).
To a 100mL round-bottomed flask, compound 4u (847mg, 2.33mmol), acetone (15mL) and 1% aqueous silver nitrate solution (4.2mL) were added in that order with magnetic stirring. The reaction was stirred at room temperature for 5h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:6, 1:2) to give 450mg of compound 5u as a yellow solid (yield 67%).
To a 10mL round-bottomed flask, compound 5u (80mg,0.27mmol), palladium acetate (6.1mg, 0.027mmol) were added under electromagnetic stirring, and finally, a 1.0mmol/mL boron trifluoride etherate solution (1.35mL, 1.35mmol) formulated with chloroform as a solvent, and finally, chloroform (5mL) were added. Reaction in an oil bath at 60 ℃ for 4h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give 68mg (yield 89%) of compound 6u as a pale yellow solid.
1H NMR(400MHz,CDCl3)8.26(dd,J=7.9,1.0Hz,1H),7.86–7.72(m,2H),7.56–7.47(m,1H),6.91(d,J=5.8Hz,1H),6.58–6.44(m,4H),1.68(d,J=1.2Hz,3H).13C NMR(100MHz,CDCl3)183.7,157.8,156.3,150.2,148.1,143.9,140.8,133.9,131.1,129.4,128.4,126.7,126.4,125.7,119.6,70.7,16.4.
Example 22: synthesis of Compound 6v
To a 250mL round bottom flask, 2v (2000mg, 12.26mmol) was added with magnetic stirring, followed by 2-bromo-4-methoxyaniline (2477mg, 12.26mmol) and finally water (60 mL). The reaction was carried out in an oil bath at 80 ℃ for 6h, a grey solid precipitated. Filtration with suction and drying gave compound 3v as a gray solid, 3500mg (89% yield).
To a 150mL round-bottom flask were added 3V (3500mg, 10.93mmol), p-toluenesulfonic acid (564mg, 3.28mmol), tetrahydrofuran (40.0mL), anhydrous magnesium sulfate (3935mg, 32.79mmol), 3-trimethylsilylpropynaldehyde (1.60mL, 10.93mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 4h, DDQ (2977mg, 13.12mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:6) to yield 690mg of compound 4v as a pale yellow solid (15% yield).
To a 100mL round bottom flask was added sequentially compound 4v (690mg, 1.6mmol), acetone (10mL) and 1% aqueous silver nitrate (2.8mL) with magnetic stirring. The reaction was stirred at room temperature for 4h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:6, 1:2) to give compound 5v as a white solid 450mg (yield 80%).
To a 10mL round bottom flask, compound 5v (60mg,0.17mmol), palladium acetate (3.8mg, 0.017mmol) and finally boron trifluoride etherate (0.95mL, 0.95mmol) prepared in 1.0mmol/mL using chloroform as a solvent were added under electromagnetic stirring, and finally chloroform (6mL) was added. Reaction in an oil bath at 30 ℃ for 15h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give compound 6v as a pale yellow solid 35mg (yield 61%).
1H NMR(400MHz,CDCl3+MeOH)8.24–8.22(m,1H),7.80–7.76(m,1H),7.74–7.72(m,1H),7.53–7.48(m,1H),7.02(d,J=1.2Hz,1H),6.96(d,J=5.8Hz,1H),6.66–6.57(m,2H),6.54(d,J=5.8Hz,1H).13C NMR(100MHz,CDCl3+MeOH)182.5,158.7,156.8,148.7,143.1,141.3,140.9,135.9,135.1,131.5,130.6,127.7,127.7,126.8,120.6,72.0.
Example 23: synthesis of Compound 6w
Under electromagnetic stirring and ice-water bath conditions, 1w (700mg, 10.00mmol) was added to a 150mL round bottom flask, followed by dichloromethane (30M) and finally chlorochromate pyridinium salt (PCC) (3888mg, 18.00mmol) and stirring at 0 ℃ for 2 h. After the reaction was completed, a large amount of the solvent was removed under reduced pressure at a low temperature to obtain a mixture containing a small amount of the solvent and the compound 4 w.
To a 250mL round bottom flask, 2w (3000mg, 18.4mmol) was added with magnetic stirring, followed by 4-methoxyaniline (2266mg, 18.4mmol) and finally water (80 mL). The reaction was carried out in an oil bath at 80 ℃ for 6h, a brown solid precipitated. Filtration with suction and drying gave compound 3w as a brown solid 3960mg (89% yield).
To a 150mL round-bottomed flask were added 3w (730mg, 3.00mmol), p-toluenesulfonic acid (155mg, 0.9mmol), tetrahydrofuran (10.0mL), anhydrous magnesium sulfate (1080mg, 9.0mmol), and the above-obtained crude product 4w in this order under electromagnetic stirring, the mixture was reacted at room temperature for 4h, DDQ (817mg, 3.60mmol) was added in an ice-water bath, the reaction was terminated, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:6) to yield 570mg of compound 5w as a pale yellow solid (66% yield).
To a 10mL round bottom flask, compound 5w (70mg,0.24mmol), palladium acetate (5.4mg, 0.024mmol) was added under magnetic stirring, and finally a 1.0mmol/mL solution of boron trifluoride in ethyl ether (1.20mL, 1.20mmol) in chloroform as solvent was added, and finally chloroform (5mL) was added. Reaction in an oil bath at 60 ℃ for 6h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1) to give compound 6w as a pale yellow solid, 30mg (yield 45%).
1H NMR(400MHz,CDCl3)8.25(dd,J=7.9,1.1Hz,1H),7.81–7.76(m,1H),7.73–7.71(m,1H),7.51–7.45(m,1H),6.67–6.61(m,3H),6.49–6.47(m,2H),1.95(d,J=1.3Hz,3H).13C NMR(125MHz,CDCl3)184.2,159.1,156.9,154.4,148.9,142.8,134.7,132.9,127.4,126.9,126.6,125.0,120.5,71.0,12.2.
Example 24: synthesis of Compound 6x
To a 250mL round bottom flask, 2X (1500mg, 9.19mmol) was added with magnetic stirring, followed by 2, 4-dimethoxyaniline (1407mg, 9.19mmol) and finally water (60 mL). The reaction was carried out in an oil bath at 80 ℃ for 5h to precipitate a purple solid. Filtration with suction and drying afforded 2100mg (84% yield) of compound 3x as a purple solid.
To a 150mL round-bottomed flask were added 3X (1500mg, 5.50mmol), p-toluenesulfonic acid (284mg, 1.65mol), tetrahydrofuran (30.0mL), anhydrous magnesium sulfate (1980mg, 16.50mmol), 3-trimethylsilylpropynaldehyde (0.85mL, 5.50mmol) in this order under electromagnetic stirring, the mixture was reacted at room temperature for 3 hours, DDQ (1498mg, 6.60mmol) was added in an ice-water bath, the reaction was carried out for 30 minutes, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (eluent: V)EA:VPE1:20, 1:10,1:4) to yield 1000mg of compound 4x as a pale yellow solid (48% yield).
To a 100mL round bottom flask was added sequentially compound 4X (1000mg, 2.64mmol), acetone (20mL) and 1% aqueous silver nitrate (4.7mL) with magnetic stirring. The reaction was stirred at room temperature for 5h in the absence of light (reaction monitored by TLC: V)EA:VPE1: 2); after the reaction was complete, extraction was carried out with ethyl acetate (4X 20mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography on silica gel (eluent: V)EA:VPE1:6, 1:2) to give compound 5x as a white solid 700mg (87% yield).
To a 10mL round bottom flask, compound 5X (100mg,0.33mmol), palladium acetate (7.30mg, 0.033mmol) were added under magnetic stirring, and finally, a 1.0mmol/mL boron trifluoride etherate solution (1.63mL, 1.63mmol) prepared using chloroform as a solvent was added, and finally, chloroform (5mL) was added. Reaction in an oil bath at 60 ℃ for 1h (reaction monitored by TLC: V)EA:VPE1:1), after the reaction was completed, saturated sodium bicarbonate solution was added to quench, extraction was performed with dichloromethane (4 × 10mL), the organic phases were combined, the solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (eluent: V)EA:VPE1:4, 1:2, 1:1, 2:1) to give compound 6x as a white solid 85mg (89% yield).
1H NMR(400MHz,CDCl3)8.25(d,J=7.6Hz,1H),7.82–7.75(m,2H),7.55–7.47(m,1H),6.86(d,J=5.8Hz,1H),6.62(d,J=5.8Hz,1H),6.53–6.50(m,1H),6.29(d,J=9.8Hz,1H),5.88(s,1H),3.68(s,3H).13C NMR(100MHz,CDCl3)186.1,167.2,158.8,157.5,149.1,143.9,137.5,134.7,131.8,129.5,127.7,127.3,126.7,120.8,104.6,70.0,56.5.
The antitumor activity of the compound prepared in the above example was preliminarily screened, and the cytotoxicity of some compounds against different tumor cells was determined by the MTT method as the antitumor activity evaluation method.
The test tests 13 compounds for their inhibitory effect on cells and the test results are shown in table 1.
The test procedure was as follows:
1) cell culture, in which LO2, NCI-H460, HepG-2, MCF-7, MCG-803 and T24 cells are revived by DMEM medium and put in CO2Culturing in an incubator, and changing the culture solution every other day. Cells in logarithmic growth phase were taken for experiments.
2) Starting from CO2Taking out cells from the incubator, removing the old culture medium, washing twice with PBS, digesting with trypsin, quickly adding a new culture medium when the cells are slightly rounded to stop cell digestion and lightly blowing and beating the suspended cells, taking a proper amount of cell culture solution, adding a certain amount of culture medium for dilution, inoculating the diluted solution into a 96-well plate, wherein each well is 180 mu L, and 200 mu L of PBS is added into each well around the 96-well plate.
3) And (3) adding medicine, namely adding samples to be detected when the cells in the 96-well plate grow to 70-80%, wherein the concentration of each sample is set to be 200 mu M/mL, and 5 auxiliary holes are set, and the concentration of each hole is 20 mu L, so that the final concentration of the sample is 20 mu M/mL. Adding compound, and adding CO2Culturing in incubator for 48 hr, adding 10 μ L of prepared MTT solution into each well, and discharging CO2And continuously culturing for 4-6 h in the incubator.
4) In the test, the culture medium in a 96-well plate is removed, 100. mu.L of DMSO is added, and the mixture is shaken on a shaking table for 8min to completely dissolve the crystallized formazan. The absorbance (OD) was measured at an absorption wavelength of 570nm and a reference wavelength of 630nm using a microplate reader, and the inhibition ratio was calculated. The inhibition rate was (1-sample group OD value/blank group OD value) × 100%, all experiments were repeated 3 times, and the average value was taken, and the relative error was calculated.
TABLE 1
As can be seen from the cytotoxicity test results of the compounds in the table 1, the novel spiro [2, 1-b ] quinazolinone derivative prepared by the invention has good anticancer effects on different tumor cells, can be prepared into anticancer drugs in various dosage forms, and has high medical value and wide market prospect.
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (9)
3. a process for the preparation of a novel spiro pyrrolo [2, 1-b ] quinazolinone derivative according to claim 1, comprising the steps of:
(1) preparation of compound 3: adding the compound 1, the compound 2 and water into a reaction container in sequence, heating, stirring for reaction, after the reaction is finished, performing suction filtration, taking filter residues, washing and drying to obtain a compound 3;
(2) preparation of compound 4: adding the compound 3, p-toluenesulfonic acid, tetrahydrofuran, anhydrous magnesium sulfate and 3-trimethylsilyl propiolic aldehyde into a reaction vessel in sequence, and reacting at room temperature; adding DDQ in an ice water bath for reaction, removing the solvent after the reaction is finished, and purifying to obtain a compound 4;
(3) preparation of compound 5: adding the compound 4, acetone and silver nitrate aqueous solution into a reaction vessel in sequence, stirring and reacting under the condition of keeping out of the sun, removing the solvent after the reaction is finished, and purifying to obtain a compound 5;
(4) preparing a target product 6: adding the compound 5, palladium acetate, boron trifluoride diethyl etherate solution and trichloromethane into a reaction vessel in sequence, heating, reacting, removing the solvent after the reaction is finished, and purifying to obtain a target product 6;
the structural formula of the compound 1 is as follows:the structural formula of compound 2 is:the structural formula of compound 3 is:the structural formula of compound 4 is:
4. the method according to claim 3, wherein the temperature of the stirring reaction in the step (1) is 75 ℃ to 85 ℃.
5. The method according to claim 3, wherein the stirring reaction time in step (1) is 8 to 10 hours.
6. The method according to claim 3, wherein the reaction time at room temperature in the step (2) is 2.5 to 3.5 hours.
7. The preparation method according to claim 3, wherein in the step (2), the DDQ is added under the ice-water bath for 25-35 min.
8. A process for the preparation of a novel spiro pyrrolo [2, 1-b ] quinazolinone derivative according to claim 1, comprising the steps of:
(1) preparation of compound 3: adding the compound 1, the compound 2 and water into a reaction container in sequence, heating, stirring for reaction, after the reaction is finished, performing suction filtration, taking filter residues, washing and drying to obtain a compound 3;
(2) preparation of compound 4': adding dichloromethane and chlorochromate pyridinium into the reaction vessel in sequence, and reacting at low temperature; after the reaction is finished, a compound 4' containing dichloromethane is obtained;
(3) preparation of compound 5': adding a compound 3, p-toluenesulfonic acid, tetrahydrofuran, anhydrous magnesium sulfate and the compound 4 'containing dichloromethane in the step (2) into a reaction container in sequence, reacting at room temperature, adding DDQ into an ice water bath after the reaction is finished, removing the solvent after the reaction is finished, and purifying to obtain a compound 5';
(4) preparing a target product 6: adding the compound 5', palladium acetate, boron trifluoride ether solution and trichloromethane into a reaction vessel in sequence, heating, stirring for reaction, removing the solvent after the reaction is finished, and purifying to obtain a target product 6;
9. the use of a novel spiro pyrrolo [2, 1-b ] quinazolinone derivative according to claim 1 for the preparation of an anti-tumor medicament.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010640945.5A CN111825679B (en) | 2020-07-06 | 2020-07-06 | Novel spiro-pyrrole [2, 1-b ] quinazolinone derivative and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010640945.5A CN111825679B (en) | 2020-07-06 | 2020-07-06 | Novel spiro-pyrrole [2, 1-b ] quinazolinone derivative and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111825679A true CN111825679A (en) | 2020-10-27 |
CN111825679B CN111825679B (en) | 2022-04-12 |
Family
ID=72900173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010640945.5A Expired - Fee Related CN111825679B (en) | 2020-07-06 | 2020-07-06 | Novel spiro-pyrrole [2, 1-b ] quinazolinone derivative and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111825679B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113480537A (en) * | 2021-06-18 | 2021-10-08 | 广西师范大学 | Quinazolinone [2,3-a ] carboline derivative and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037291A (en) * | 2015-06-11 | 2015-11-11 | 武汉大学 | Preparation method of isatoic anhydride derivative |
CN110724153A (en) * | 2019-09-11 | 2020-01-24 | 广西师范大学 | Quinazolinone derivative and preparation method and application thereof |
-
2020
- 2020-07-06 CN CN202010640945.5A patent/CN111825679B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037291A (en) * | 2015-06-11 | 2015-11-11 | 武汉大学 | Preparation method of isatoic anhydride derivative |
CN110724153A (en) * | 2019-09-11 | 2020-01-24 | 广西师范大学 | Quinazolinone derivative and preparation method and application thereof |
Non-Patent Citations (2)
Title |
---|
王增博 等: ""基于芳基烯胺酯的环化反应合成苯并菲啶类似物及其细胞毒活性研究"", 《有机化学》 * |
王淑琴等: "哒嗪并[6,1-b]喹唑啉酮类化合物的合成及其生物活性", 《有机化学》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113480537A (en) * | 2021-06-18 | 2021-10-08 | 广西师范大学 | Quinazolinone [2,3-a ] carboline derivative and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN111825679B (en) | 2022-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111087285B (en) | Method for extracting bibenzyl compounds from dendrobium officinale and application of bibenzyl compounds | |
CN101560198A (en) | New isoandrographolidume sulfonate, pharmaceutical composition containing sulfonate, preparation method and applications thereof | |
CN111825679B (en) | Novel spiro-pyrrole [2, 1-b ] quinazolinone derivative and preparation method and application thereof | |
CN114736214B (en) | Sesquiterpene derivative, pharmaceutical composition thereof, and preparation method and application thereof | |
CN106892902A (en) | A kind of hydrochloric acid is for a pyrimidine and its synthetic method of the chloromethyluracil of intermediate 6 | |
CN107722101A (en) | Steroidal pyridine derivatives and its preparation method and application | |
CN101270102A (en) | Process for synthesizing parthenolide derivative and uses thereof | |
CN116284018A (en) | Preparation method and application of furo [2,3-b ] quinoline derivative | |
CN102344475A (en) | Scutellarin derivative and preparation method and application thereof | |
CN108864089B (en) | Indolopyridone drug molecule and preparation method and application thereof | |
CN108014113A (en) | Application of butyrylamidodimethoxybenzo [ d ] aza-based quinazoline compound in preparation of drugs for treating cervical cancer | |
CN108078994A (en) | 6- (2- morpholinyls acetylamino) quinazoline compounds are preparing the application in treating lung-cancer medicament | |
CN108042546A (en) | Morpholinyl acetylamino benzo [d] azepine * bases quinazoline compounds are preparing the application in treating uterine neck cancer drug | |
CN101270119B (en) | Technique for purifying spherosinin from leguminosae pointvetch or milk vetch | |
CN108484623B (en) | Camptothecin derivative and preparation method and application thereof | |
CN115246869A (en) | Tripterine-thiazolidinedione derivative as well as preparation method and application thereof | |
CN106117244A (en) | The process for purification of Cefditoren pivoxil Cephalosporins | |
CN102260173A (en) | Ferulic acid derivative of Glaucocalyxin A, its preparation method and its application | |
CN111333650A (en) | Method for preparing hypoxanthine by inosine hydrolysis method | |
CN105753820B (en) | A kind of method of purification of dehydroandrographolide succinate | |
CN113845483B (en) | Pink back pteridonic acid and 5-fluorouracil hybrid, preparation method and application thereof | |
CN108014112A (en) | Adjacent toluidino acetylamino benzo [d] azepine * bases quinazoline compounds are preparing the application in treating lung-cancer medicament | |
CN111454274A (en) | Preparation method of sesquiterpene lactone-SAHA derivative and application of sesquiterpene lactone-SAHA derivative in preparation of anti-cancer drugs | |
CN114957272B (en) | Chromane dimer and preparation method and application thereof | |
CN108295076A (en) | Propionamido dimethoxy benzo [d] azepine * bases quinazoline ditosylate salt is preparing the application in treating lung-cancer medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220412 |
|
CF01 | Termination of patent right due to non-payment of annual fee |